CRISPR Therapeutics, Inc.

CRISPR Therapeutics' CTX310, an in vivo ANGPTL3 knockout therapy, demonstrated peak reductions of up to 82% in triglycerides and 86% in LDL cholesterol at dose level four in Phase 1 trial results.

Oruka Therapeutics has promoted Laura Sandler to Chief Operating Officer, leveraging her 20+ years of biopharmaceutical experience including her role in advancing CRISPR's first approved therapy exa-cel.

Tourmaline Bio's antibody drug pacibekitug demonstrated significant reduction in cardiovascular risk biomarkers compared to placebo in Phase 2 trials, but shares fell 18% as investors question its competitive edge against Novo Nordisk's offering.

CRISPR Therapeutics is diversifying beyond gene editing through a strategic $95 million partnership with Sirius Therapeutics to develop SRSD107, a long-acting siRNA therapy targeting Factor XI for thromboembolic disorders.

Capsida Biotherapeutics has received FDA IND clearance for CAP-002, the first intravenously administered gene therapy that crosses the blood-brain barrier while avoiding off-target tissues for STXBP1-DEE.

• Comprehensive analysis of 700+ pharmaceutical and biotechnology partnering deals with disclosed royalty rates from 2010-2025 has been published by ResearchAndMarkets.com. • The report provides unprecedented access to actual contract documents submitted to the SEC, offering detailed insights into royalty rate structures and their integration with other financial terms. • Key industry players including AbbVie, Pfizer, Novartis, and Bristol-Myers Squibb are featured among the 50+ companies actively disclosing royalty rates in their partnership agreements.

Bengaluru-based NKure Therapeutics and CRISPR Therapeutics have formed a strategic partnership to co-develop CTX112, a next-generation allogeneic CAR-T therapy for B-cell malignancies in India.

CRISPR Therapeutics and Vertex report encouraging progress with Casgevy, their approved gene therapy for sickle cell disease and beta-thalassemia, with 65 treatment centers now activated globally.

Capsida Biotherapeutics will present seven scientific presentations at ASGCT 2025, showcasing progress on their engineered AAV gene therapies targeting neurological disorders.

Despite 32 approved gene therapies globally, the industry faces significant challenges in safety, efficacy, and affordability, prompting development of novel delivery systems beyond traditional viral vectors.